These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 8160445)
1. [The immunogenic properties and prophylactic efficacy of a live polyvalent influenza vaccine in children 5 to 14 years old]. Grigor'eva EP; Rekstin AR; Rudenko LG; Ramirez A; Barro M; Lisovskaia KV; Klimov AI; Aleksandrova GI Vopr Virusol; 1994; 39(1):26-9. PubMed ID: 8160445 [TBL] [Abstract][Full Text] [Related]
2. [The inoculation properties of live recombinant influenza vaccine types A and B used separately and jointly in children 3 to 14]. Rudenko LG; Ramirez A; Barro M; Gushchina MI; Armanda RE; Ermachenko TA; Romanova IuR; Grigor'eva EP; Aleksandrova GI; Lonskaia NI Vopr Virusol; 1991; 36(6):472-4. PubMed ID: 1785181 [TBL] [Abstract][Full Text] [Related]
3. [A comparative study of live and inactivated influenza vaccines: the organization of the observation and the results of a study of their reactogenicity and immunogenicity]. Slepushkin AN; Rudenko LG; Kendal AP; Monto AS; Beliaev AL; Burtseva EI; Grigor'eva EP; Obrosova-Serova NP; Ivanova VT; Bragina VE Vopr Virusol; 1994; 39(3):129-31. PubMed ID: 8091754 [TBL] [Abstract][Full Text] [Related]
5. [The formation of an immune response in volunteers inoculated with a live recombinant influenza vaccine]. Vorob'ev KV; Rudenko LG; Islamova IT; Grigor'eva EP; Egorov AIu; Ermachenko TA; Chepik EB; Zakharova NG; Karachentsev AM Vopr Virusol; 1991; 36(6):475-7. PubMed ID: 1785182 [TBL] [Abstract][Full Text] [Related]
6. Efficacy of inactivated vaccine in preventing antigenically drifted influenza type A and well-matched type B. Sugaya N; Nerome K; Ishida M; Matsumoto M; Mitamura K; Nirasawa M JAMA; 1994 Oct; 272(14):1122-6. PubMed ID: 7933325 [TBL] [Abstract][Full Text] [Related]
7. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. Belshe RB; Mendelman PM; Treanor J; King J; Gruber WC; Piedra P; Bernstein DI; Hayden FG; Kotloff K; Zangwill K; Iacuzio D; Wolff M N Engl J Med; 1998 May; 338(20):1405-12. PubMed ID: 9580647 [TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of live attenuated and inactivated influenza vaccines in children with cancer. Carr S; Allison KJ; Van De Velde LA; Zhang K; English EY; Iverson A; Daw NC; Howard SC; Navid F; Rodriguez-Galindo C; Yang J; Adderson EE; McCullers JA; Flynn PM J Infect Dis; 2011 Nov; 204(10):1475-82. PubMed ID: 21949042 [TBL] [Abstract][Full Text] [Related]
10. [Safety of an influenza-split-vaccine in children]. Schmitt-Grohé S; Banzhoff A; Klaassen B; Zielen S Klin Padiatr; 2001; 213(6):338-42. PubMed ID: 11713714 [TBL] [Abstract][Full Text] [Related]
11. Efficacy and effectiveness of live attenuated influenza vaccine in school-age children. Coelingh K; Olajide IR; MacDonald P; Yogev R Expert Rev Vaccines; 2015; 14(10):1331-46. PubMed ID: 26372891 [TBL] [Abstract][Full Text] [Related]
12. Influenza immunisation in children with solid tumours. Chisholm J; Howe K; Taj M; Zambon M Eur J Cancer; 2005 Oct; 41(15):2280-7. PubMed ID: 16143516 [TBL] [Abstract][Full Text] [Related]
13. Influenza vaccine 2008-2009. Med Lett Drugs Ther; 2008 Oct; 50(1296):77-9. PubMed ID: 18833032 [TBL] [Abstract][Full Text] [Related]
14. Prospects for universal influenza virus vaccine. Gerhard W; Mozdzanowska K; Zharikova D Emerg Infect Dis; 2006 Apr; 12(4):569-74. PubMed ID: 16704803 [TBL] [Abstract][Full Text] [Related]
15. Vaccine for prevention of mild and moderate-to-severe influenza in children. Jain VK; Rivera L; Zaman K; Espos RA; Sirivichayakul C; Quiambao BP; Rivera-Medina DM; Kerdpanich P; Ceyhan M; Dinleyici EC; Cravioto A; Yunus M; Chanthavanich P; Limkittikul K; Kurugol Z; Alhan E; Caplanusi A; Durviaux S; Boutet P; Ofori-Anyinam O; Chandrasekaran V; Dbaibo G; Innis BL N Engl J Med; 2013 Dec; 369(26):2481-91. PubMed ID: 24328444 [TBL] [Abstract][Full Text] [Related]
16. [A comparative study of the inoculation properties of live recombinant and inactivated influenza vaccines made from strain A/Philippines/2/82 (H3N2) in 8- to 15-year-old children]. Slepushkin AN; Obrosova-Serova NP; Burtseva EI; Govorkova EA; Rudenko LG; Vartanian RV; Vereshchinskiĭ AI; Musina MD; Lonskaia NI; Zazimko LA Vopr Virusol; 1991; 36(5):372-4. PubMed ID: 1803766 [TBL] [Abstract][Full Text] [Related]
17. Current status of live attenuated influenza virus vaccine in the US. Belshe RB Virus Res; 2004 Jul; 103(1-2):177-85. PubMed ID: 15163507 [TBL] [Abstract][Full Text] [Related]
18. Serum antibody responses after intradermal vaccination against influenza. Belshe RB; Newman FK; Cannon J; Duane C; Treanor J; Van Hoecke C; Howe BJ; Dubin G N Engl J Med; 2004 Nov; 351(22):2286-94. PubMed ID: 15525713 [TBL] [Abstract][Full Text] [Related]
19. [The evaluation of the reactogenicity and immunological activity of an inactivated 3-component influenza vaccine with an elevated hemagglutinin concentration in the inoculation dosage]. Marinich IG; Shadrin AS; Naĭkhin AN; Ivannikov IuG; Kuznetsov NP; Karogodina VI; Shcherbinskaia AM; Voronina EG; Stepankovskaia LD; Eliseeva IV Zh Mikrobiol Epidemiol Immunobiol; 1991 Jul; (7):58-61. PubMed ID: 1950267 [TBL] [Abstract][Full Text] [Related]
20. [The results of state trials of inactivated influenza vaccines for children]. Vasil'eva RI; Smirnova LA; Rudenko LG; Drinevskiĭ VP; Tsaritsina IM Zh Mikrobiol Epidemiol Immunobiol; 1988 Mar; (3):49-54. PubMed ID: 2968738 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]